Glucagon-like peptide-1 7-36: a physiological incretin in man
- PMID: 2890903
- DOI: 10.1016/s0140-6736(87)91194-9
Glucagon-like peptide-1 7-36: a physiological incretin in man
Abstract
The physiological role of glucagon-like peptide-1 7-36 amide (GLP-1 7-36) in man was investigated. GLP-1 7-36-like immunoreactivity was found in the human bowel; its circulating level rose after oral glucose and after a test breakfast. When it was infused into seven volunteers at a rate to mimic its postprandial plasma concentration in the fasting state, plasma insulin levels rose significantly and glucose and glucagon concentrations fell. During an intravenous glucose load, it greatly enhanced insulin release and significantly reduced peak plasma glucose concentrations, compared with a control saline infusion, even inducing postinfusion reactive hypoglycaemia. By comparison, infusion of glucose-dependent insulinotropic peptide (GIP) to physiological levels was less effective in stimulating insulin release. These observations suggest that GLP-1 7-36 is a physiological incretin and that it is more powerful than GIP. The observation of greatly increased postprandial plasma GLP-1 7-36 levels in patients with postgastrectomy dumping syndrome suggests that it may mediate the hyperinsulinaemia and reactive hypoglycaemia of this disorder.
Similar articles
-
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.J Clin Endocrinol Metab. 1993 Apr;76(4):912-7. doi: 10.1210/jcem.76.4.8473405. J Clin Endocrinol Metab. 1993. PMID: 8473405 Clinical Trial.
-
Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.Diabetologia. 1998 Oct;41(10):1180-6. doi: 10.1007/s001250051049. Diabetologia. 1998. PMID: 9794105
-
Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.Z Gastroenterol. 1996 Mar;34(3):159-66. Z Gastroenterol. 1996. PMID: 8650968
-
Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.Dan Med J. 2016 Apr;63(4):B5230. Dan Med J. 2016. PMID: 27034187 Review.
-
Incretin hormones: Their role in health and disease.Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. doi: 10.1111/dom.13129. Diabetes Obes Metab. 2018. PMID: 29364588 Review.
Cited by
-
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.Clin Lipidol. 2015;10(1):103-112. doi: 10.2217/clp.14.59. Clin Lipidol. 2015. PMID: 26005496 Free PMC article.
-
A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin.CPT Pharmacometrics Syst Pharmacol. 2020 Jun;9(6):353-362. doi: 10.1002/psp4.12520. Epub 2020 Jun 16. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32543789 Free PMC article.
-
Roux-en-Y gastric bypass operation in rats.J Vis Exp. 2012 Jun 11;(64):e3940. doi: 10.3791/3940. J Vis Exp. 2012. PMID: 22710348 Free PMC article.
-
Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.Obes Surg. 2013 Sep;23(9):1354-60. doi: 10.1007/s11695-013-0921-3. Obes Surg. 2013. PMID: 23526068
-
Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.J Biol Chem. 2016 Jul 22;291(30):15778-87. doi: 10.1074/jbc.M116.724542. Epub 2016 May 10. J Biol Chem. 2016. PMID: 27226591 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
